spacer
home > ict > winter 2021 > the apac advantages
PUBLICATIONS
International Clinical Trials

The APAC Advantages


The search for a treatment or vaccine to alleviate the COVID-19 pandemic has put the clinical trials process firmly in the spotlight. However, even before this, pharmaceutical companies have been looking increasingly towards the countries of the Asia-Pacific (APAC) region as a place to carry out clinical trials, as it offers several advantages over the traditional locations of the US and Europe.

Asia is the most populated continent in the world, with more than half of the total global population. It is also home to heterogeneous population groups, and many treatment-naÔve patients. Furthermore, the high incidence of certain diseases in some Asian countries, for example, liver and lung cancers, makes them the preferred recruitment site for treatment trials for such conditions.

The cost of locating a clinical trial in Asia can also be significantly lower than in the US or Europe, with savings typically estimated at 30-40% (1). For example, the cost for each patient per visit in China, India, and Thailand combined is nearly equivalent to the per patient per visit cost in the US alone. Additionally, individual APAC countries have implemented strategies to encourage clinical trials, such as tax and custom exemptions to encourage productivity and profitability, and have expedited clinical trial registration and approval.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Daniel Gao is General Manager ofCatalent's clinical supply facilities, Shanghai, China. In this role, he oversees clinical supply operations in China with an emphasis on local strategy, service delivery, quality, and operational excellence. His previous roles at Catalent include Account Director of Greater China, where he focused on developing business for Catalent China and the APAC region. Prior to joining Catalent, Daniel was the Head of Clinical Trials, China, for Cardinal Health. He holds an MBA from Ryerson University, Canada, with a specialisation in Supply Chain Management, and a Masterís degree in Project Management from Manchester University, UK.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases

Funding accelerates development of late-stage cancer therapies, pipeline expansion and business growth Syndicate includes all Series A investors, preeminent life science and generalist funds, and market-leading health systems and payers
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world Ė in Europe and Asia in particular Ė disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than todayís differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. Itís also important to choose a solution that enables multi-phase implementation
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement